Metabolic Syndrome and Obesity Up Risk of Mortality in CRC

This article originally appeared here.
Share this content:
Metabolic Syndrome and Obesity Up Risk of Mortality in CRC
Metabolic Syndrome and Obesity Up Risk of Mortality in CRC

TUESDAY, Sept. 13, 2016 (HealthDay News) -- For patients with early-stage colorectal cancer (CRC), the presence of metabolic syndrome (MetSyn) and obesity is associated with increased risk of mortality, according to a study published online Sept. 6 in the Journal of Clinical Oncology.

Elizabeth M. Cespedes Feliciano, Sc.D., from Kaiser Permanente Northern California in Oakland, and colleagues studied 2,446 patients with early-stage CRC diagnosed from 2006 to 2011. Participants were classified according to the presence or absence of MetSyn and obesity.

The researchers found that 601 patients died over a median follow-up of six years, 325 as a result of CRC. For overall survival the hazard ratios were 1.45 for obese patients with MetSyn (95 percent confidence interval [CI], 1.12 to 1.82); 1.09 for non-obese with MetSyn (95 percent CI, 0.83 to 1.44); and 1.00 for obese patients without MetSyn (95 percent CI, 0.80 to 1.26), compared to non-obese patients without MetSyn. CRC-related survival was predicted by obesity with MetSyn (hazard ratio, 1.49; 95 percent CI, 1.09 to 2.02). There was an increase in the risk of death with the number of MetSyn components present, which was independent of obesity.

"Patients with early-stage CRC with obesity and MetSyn have worse survival, overall and CRC related," the authors write.

Two authors disclosed financial ties to the biopharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »